Pubfacts - Scientific Publication Data
  • Categories
  • Journals
  • ->
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:
Get 20% Off Journals at LWW.com

Optimizing Genetic Diagnosis of Neurodevelopmental Disorders in the Clinical Setting.

Authors:
David Joshua Michelson Robin Dawn Clark

Clin Lab Med 2020 09 3;40(3):231-256. Epub 2020 Jul 3.

Division of Medical Genetics, Department of Pediatrics, Loma Linda University School of Medicine, Coleman Pavilion Room A, 1175 Campus Street, Loma Linda, CA 92354, USA.

Progress in medical genetics has changed the practice of medicine in general and child neurology in particular. A genetic diagnosis has become critically important in determining optimal management of many neurodevelopmental disorders, making genetic testing a routine consideration of patient care in outpatient and inpatient settings. Today's child neurologists should be familiar with various genetic testing modalities and their appropriate use. Molecular genetic testing of children with unexplained developmental delays and/or congenital anomalies has a 20% to 30% chance of identifying a causative etiology. Newer methods have made genetic testing more widely available and sensitive but also more likely to produce ambiguous results.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cll.2020.05.001DOI Listing
September 2020

Publication Analysis

Top Keywords

genetic testing
16
neurodevelopmental disorders
8
genetic diagnosis
8
genetic
5
neurologists familiar
4
child neurologists
4
today's child
4
testing modalities
4
appropriate molecular
4
modalities appropriate
4
settings today's
4
familiar genetic
4
outpatient inpatient
4
testing routine
4
testing
4
making genetic
4
routine consideration
4
consideration patient
4
molecular genetic
4
patient care
4

Altmetric Statistics


Show full details
4 Total Shares
4 Tweets
4 Citations

Similar Publications

A fetal reduction from twin to singleton based on sonography and cell-free fetal DNA testing: A sequential approach to old pitfalls.

Authors:
Yaakov Melcer Ran Svirsky Shira Dvash Marina Pekar-Zlotin Hamutal Meiri Ron Maymon

Eur J Obstet Gynecol Reprod Biol 2021 Feb 17;259:105-112. Epub 2021 Feb 17.

Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (Formerly Assaf Harofeh Medical Center), Zerifin, Israel, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Objective: We examined the potential value of combining ultrasound and non-invasive prenatal screening (NIPS) of maternal blood to screen for major aneuploidies as an early approach before selective fetal reduction from twin pregnancy to singleton.

Study Design: The sample was composed of pregnant women with di-chorionic di-amniotic twins who chose to undergo fetal reduction to singleton at 12-24 weeks of gestation. These women were asked to provide a blood sample for cell-free fetal DNA (cffDNA) testing prior to fetal reduction. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

A multidisciplinary fetal neurosurgical service-5 years of fetal outcomes from a national referral centre.

Authors:
Clare O'Connor Peter McParland Darach Crimmins John Caird Barbara Cathcart Heather Hughes Gabrielle Colleran Rhona Mahony Shane Higgins Stephen Carroll Jennifer Walsh Fionnuala M McAuliffe

Ir J Med Sci 2021 Feb 27. Epub 2021 Feb 27.

Fetal Medicine, National Maternity Hospital, Dublin 2, Ireland.

Background: A specialist fetal neurosurgical clinic was set up in order to improve patient care in a tertiary referral fetal medicine centre. The clinic provides a targeted clinical service for women diagnosed with fetal neurological abnormalities. The service consists of fetal MRI, fetal ultrasound and joint assessment and counselling from neurosurgery and fetal medicine teams. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Genetic ataxias: update on classification and diagnostic approaches.

Authors:
Natalie Witek Jacob Hawkins Deborah Hall

Curr Neurol Neurosci Rep 2021 Feb 26;21(3):13. Epub 2021 Feb 26.

Rush Parkinson's Disease and Movement Disorders Program, 1725 W Harrison St. Suite 755, Chicago, IL, 60612, USA.

Ataxia encompasses a large group of rare disorders characterized by irregular movements, decreased coordination, imbalance, kinetic tremor, wide-based stance, and dysarthria. Evaluating ataxia can be challenging considering the volume of disorders and their complex pathologies involving diverse genetic and clinical factors. This is a comprehensive review of the genetic ataxia literature, presenting updated guidelines for differential diagnosis. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

The impact of unsolicited findings in clinical exome sequencing, a qualitative interview study.

Authors:
Vyne van der Schoot Simone J Viellevoije Femke Tammer Han G Brunner Yvonne Arens Helger G Yntema Anke J M Oerlemans

Eur J Hum Genet 2021 Feb 26. Epub 2021 Feb 26.

Department of Human Genetics, Donders Centre for Neuroscience, Radboud university medical center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.

Unsolicited findings (UFs) in clinical exome sequencing are variants that are unrelated to the initial clinical question the DNA test was performed for, but that may nonetheless be of medical relevance to patients and/or their families. There is limited knowledge about the impact of UFs on patients' lives. In order to characterise patient perceptions of the impact of an UF, we conducted 20 semi-structured face-to-face interviews with patients and/or their relatives to whom an UF predisposing to oncological disease (n = 10) or predisposing to a cardiac condition (n = 10) had been disclosed. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.

Authors:
Richard S P Huang James Haberberger Karthikeyan Murugesan Natalie Danziger Matthew Hiemenz Eric Severson Daniel L Duncan Shakti H Ramkissoon Jeffrey S Ross Julia A Elvin Douglas I Lin

Mod Pathol 2021 Feb 26. Epub 2021 Feb 26.

Foundation Medicine, Inc., Cambridge, MA, USA.

Positive program death-ligand 1 (PD-L1) immunohistochemistry (IHC) is an approved companion diagnostic guiding the use of immune checkpoint inhibitors in uterine cervical carcinoma (CXC). The clinical and genomic features of PD-L1-positive (PD-L1) CXC have not been previously described. We reviewed the clinicopathologic and molecular features of 647 CXC cases that were tested using DAKO 22C3 PD-L1 IHC and comprehensive genomic profiling during the course of clinical care. Read More

View Article and Full-Text PDF
February 2021
Similar Publications
Save 15% Survey
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap